Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases

• A. J. Conde-Moreno ^[6] ; J. L. Lopez-Guerra ^[1] ; V. A. Macias ^[7] ; M. L. Vázquez de la Torre ^[8] ; P. Samper Ots ^[2] ; S. San José-Maderuelo ^[3] ; J. Pastor Peidro ^[4] ; J. López-Torrecilla ^[4] ; J. Expósito-Hernández ^[5]
  1. [1] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  2. [2] Hospital Universitario Rey Juan Carlos

     Hospital Universitario Rey Juan Carlos

     Móstoles, España

     
  3. [3] Centro Medico Teknon

     Centro Medico Teknon

     Barcelona, España

     
  4. [4] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  5. [5] Hospital Universitario Virgen de las Nieves

     Hospital Universitario Virgen de las Nieves

     Granada, España

     
  6. [6] Hospital Provincial de Castellon, España
  7. [7] Hospital Universitario Salamanca, España
  8. [8] Hospital Meixoeiro-Galaria, Vigo, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 4 (April 2016), 2016, págs. 342-351
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Data in the literature support the existence of a state of limited metastases or oligometastases. Favorable outcomes have been observed in selected patients with such oligometastases that are treated with local ablative therapies, which include surgical extirpation, stereotactic body radiation therapy (SBRT), and radiofrequency ablation. The role of SBRT in the setting of lymph node oligometastases is still emerging but the early results for local control are promising. However, the biggest challenge is to identify patients who will benefit from treatment of their oligometastatic disease with local aggressive therapy. Patients are initially categorized based upon examination of the initial biopsy, location, stage, and previous treatments received. Appropriate patient management with SBRT requires an understanding of several clinicopathological features that help to identify several subsets of patients with more responsive tumors and a good tolerance to SBRT. In an effort to incorporate the most recent evidence, here the Spanish Society of Radiation Oncology presents guidelines for using SBRT in lymph node oligometastases.